Drug Trial Radar · NCT00645255
Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects
Last checked: Nov 20, 2026Latest source record: Mar 27, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
466
Actual
Start
Sep 1998
Primary completion
Jan 2003
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- Mar 27, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study was designed to evaluate the long term efficacy and safety of Meridia 15 mg daily in obese subjects.
Conditions
- Obesity
- Weight Loss
Interventions
placeboDrug
placebo one capsule daily
sibutramine or placeboDrug
one capsule daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Body Weight LossTime frame: Mean Change From Baseline
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.